18398367. POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING IL-6 AND TNF ALPHA simplified abstract (SANOFI)

POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING IL-6 AND TNF ALPHA

Organization Name

SANOFI

Inventor(s)

Heidi Rommelaere of Gent (BE)

Christian Asbrand of Frankfurt Am Main (DE)

Nadine Biesemann of Frankfurt am Main (DE)

Ann Brige of Ertvelde (BE)

Sigrid Cornelis of St. Martens-Latem (BE)

Karen Heyninck of Zwijnaarde (BE)

Eric Lorent of Zwijnaarde (BE)

Shanna Van Zwam of Zwijnaarde (BE)

POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING IL-6 AND TNF ALPHA - A simplified explanation of the abstract

This abstract first appeared for US patent application 18398367 titled 'POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING IL-6 AND TNF ALPHA

The present disclosure introduces a new type of drug for treating inflammatory and/or autoimmune diseases, specifically rheumatoid arthritis. This drug consists of polypeptides with at least three immunoglobulin single variable domains (ISVDs), where one ISVD binds to TNF-α and at least two ISVDs bind to IL-6.

• Polypeptides with at least three ISVDs
• One ISVD binds to TNF-α, while at least two ISVDs bind to IL-6
• Designed for treating inflammatory and autoimmune diseases, particularly rheumatoid arthritis
• Nucleic acids, vectors, and compositions are also provided in the disclosure

Potential Applications: - Treatment of rheumatoid arthritis - Management of other inflammatory and autoimmune diseases

Problems Solved: - Addressing inflammation and autoimmune responses in the body - Providing a targeted treatment for rheumatoid arthritis

Benefits: - Specific binding capabilities to key inflammatory markers - Potential for more effective and targeted treatment - Reduced side effects compared to traditional therapies

Commercial Applications: Title: Innovative Drug for Rheumatoid Arthritis Treatment This technology could be utilized in pharmaceutical companies for the development of new treatments for rheumatoid arthritis and other inflammatory conditions. It may also have applications in research institutions studying autoimmune diseases.

Questions about the technology: 1. How does the binding of ISVDs to TNF-α and IL-6 contribute to the treatment of rheumatoid arthritis? 2. What sets this drug apart from existing treatments for inflammatory and autoimmune diseases?

Original Abstract Submitted

The present disclosure provides a novel type of drug for treating a subject suffering from an inflammatory and/or autoimmune disease, and specifically rheumatoid arthritis. Specifically, the disclosure provides polypeptides comprising at least three immunoglobulin single variable domains (ISVDs), characterized in that at least one ISVD binds to TNF-α and at least two ISVDs bind to IL-6. The present disclosure also provides nucleic acids, vectors and compositions.